US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

26.34

+0.47001.82%

Post-market: 26.340.00000.00%16:20 EDT

Volume:226.52K

Turnover:5.88M

Market Cap:741.37M

PE:-11.26

High:26.44

Open:26.34

Low:24.86

Close:25.87

Loading ...

Overview Company News Filings

Relmada Therapeutics presents initial Phase 2 NDV-01 data at AUA2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment

MT Newswires Live

Merck KGaA's $3.9B SpringWorks Therapeutics Buy Underwhelms -- Market Talk

Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities

Press Release: Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million

Protara Therapeutics: Promising Clinical Progress and Strong Buy Rating Amid Encouraging ADVANCED-2 Study Results

SpringWorks Therapeutics downgraded to Equal Weight from Overweight at Barclays

Tvardi Therapeutics Initiated at Buy by Jones Trading

Wedbush Downgrades Springworks Therapeutics to Neutral From Outperform, Adjusts PT to $47 From $81

MT Newswires Live

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Protara Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.

Appili Therapeutics granted new patents for LIKMEZ

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright

PYC Therapeutics Announces Change in Substantial Shareholder Interests

Springworks Therapeutics Agrees to $47-Per-Share Takeover Offer From Germany's Merck

MT Newswires Live

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=14"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":26.34,"timestamp":1746820800000,"preClose":25.87,"halted":0,"volume":226520,"hourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"delay":0,"floatShares":11456571,"shares":28146154,"eps":-2.338654,"marketStatus":"Market Closed","change":0.47,"latestTime":"05-09 16:00:00 EDT","open":26.34,"high":26.44,"low":24.86,"amount":5880456.606978,"amplitude":0.061075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.338654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":25.87,"preHourTrading":{"tag":"盘前","latestPrice":26.3,"preClose":25.87,"latestTime":"09:29 EDT","volume":321,"amount":8435.569914,"timestamp":1746797398443},"postHourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"volumeRatio":0.8674420486669012,"impliedVol":0.6531,"impliedVolPercentile":0.8182},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11456571,"roa":"-17.75%","roe":"-24.47%","lyrEps":-2.338654,"volumeRatio":0.8674420486669012,"shares":28146154,"dividePrice":0,"high":26.44,"amplitude":0.061075,"preClose":25.87,"low":24.86,"week52Low":14.42,"pbRate":"3.86","week52High":38.93,"institutionHeld":0,"latestPrice":26.34,"eps":-2.338654,"divideRate":0,"volume":226520,"delay":0,"ttmEps":-2.338654,"open":26.34,"prevYearClose":28.87,"prevWeekClose":29.52,"prevMonthClose":28.515,"prevQuarterClose":25.71,"fiveDayClose":29.52,"twentyDayClose":18.54,"sixtyDayClose":24.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:14,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531568922","title":"Relmada Therapeutics presents initial Phase 2 NDV-01 data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531568922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531568922?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:46","pubTimestamp":1745862373,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics (RLMD) announced that “positive” initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-presents-initial-phase-2-ndv-01-data-at-aua2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-presents-initial-phase-2-ndv-01-data-at-aua2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","RLMD"],"gpt_icon":0},{"id":"2531558002","title":"Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531558002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531558002?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:38","pubTimestamp":1745861880,"startTime":"0","endTime":"0","summary":"90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*. NDV-01 showed promising clinical activity in BCG-nave and BCG-unresponsive patients, with favorable overall tolerability. Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET. CORAL GABLES, Fla., April 28, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point following treatment, demonstrating strong clinical activity and supporting further development of NDV-01 for the treatment of non-muscle invasive bladder cancer . The data were presented today at the American Urology Association 2025  Annual Meeting with a data cutoff date of April 20, 2025. To register for the virtual Investor Event, click here.Overall: The trea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-presents-positive-initial-173800225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ORR","LENZ","RLMD","CR","BK4161","BK4139"],"gpt_icon":0},{"id":"2531925815","title":"Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925815","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531925815?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:17","pubTimestamp":1745860632,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics  reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.Shares of the company rose 1.5% in recent Monday trading.Price: 1.33, Change: +0.02, Percent Change: +1.53","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","CMMB","LENZ"],"gpt_icon":0},{"id":"2530350632","title":"Merck KGaA's $3.9B SpringWorks Therapeutics Buy Underwhelms -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2530350632","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530350632?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:20","pubTimestamp":1745853600,"startTime":"0","endTime":"0","summary":"1119 ET - Merck KGaA's acquisition of SpringWorks Therapeutics for $47 per share, or $3.9 billion in total, carried an underwhelming price tag to say the least, Evercore ISI analysts say in a research note. The analysts expected an agreement to price shares in the $60s, which would have still been highly attractive for the buyer, they said. The final deal price net of cash represents just two times the company's consensus peak sales, the analysts said, adding they can't recall such a low multiple for a company not in distress. \"Hopefully this transaction is not a broader indictment on the state of biotech M&A amidst a difficult backdrop,\" the analysts say. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MKKGY","LENZ","SWTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2530238784","title":"Summit Therapeutics Price Target Maintained With a $40.00/Share by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2530238784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530238784?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:53","pubTimestamp":1745851980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SMMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2025 10:53 ET (14:53 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","JMP","LENZ","SMMF"],"gpt_icon":0},{"id":"2530840242","title":"Press Release: Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2530840242","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530840242?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:19","pubTimestamp":1745849940,"startTime":"0","endTime":"0","summary":"Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million. Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases. Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026. The combined company will operate as \"Jade Biosciences, Inc.\" and will trade on Nasdaq under the ticker symbol \"JBIO\". SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025  -- Jade Biosciences, Inc. , a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. . The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on April 29, 2025, under the ticker symbol \"JBIO.\". Follow","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","AVTE","BK4139","JBIO"],"gpt_icon":0},{"id":"2530289407","title":"Protara Therapeutics: Promising Clinical Progress and Strong Buy Rating Amid Encouraging ADVANCED-2 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530289407","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530289407?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:45","pubTimestamp":1745847918,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics (TARA – Research Report), retaining the price target of $22....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/protara-therapeutics-promising-clinical-progress-and-strong-buy-rating-amid-encouraging-advanced-2-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/protara-therapeutics-promising-clinical-progress-and-strong-buy-rating-amid-encouraging-advanced-2-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","AEIS","PRGS"],"gpt_icon":0},{"id":"2530285066","title":"SpringWorks Therapeutics downgraded to Equal Weight from Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2530285066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530285066?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:35","pubTimestamp":1745847340,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson downgraded SpringWorks Therapeutics (SWTX) to Equal Weight from Overweight with a price target of $47, down from $63,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/springworks-therapeutics-downgraded-to-equal-weight-from-overweight-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/springworks-therapeutics-downgraded-to-equal-weight-from-overweight-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2530401593","title":"Tvardi Therapeutics Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2530401593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530401593?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:24","pubTimestamp":1745843040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2025 08:24 ET (12:24 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","TVRD"],"gpt_icon":0},{"id":"2530409808","title":"Wedbush Downgrades Springworks Therapeutics to Neutral From Outperform, Adjusts PT to $47 From $81","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409808","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409808?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:17","pubTimestamp":1745842673,"startTime":"0","endTime":"0","summary":"Springworks Therapeutics (SWTX) has an average rating of buy and mean price target of $71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SWTX","LENZ","PT"],"gpt_icon":0},{"id":"2530282204","title":"Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530282204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530282204?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with tovecimig  markedly increased anti-tumor efficacy in these models.Tovecimig in combination with CTX-471 showed evidence of enhanced innate and adaptive anti-tumor immunity ranging from increased tumor cell killing to increased antigen presentation and interferon signaling.The combination of tovecimig and CTX-471 has the potential to be an effective therapeutic regimen in patients where checkpoint inhibitors have failed, including anti-PD-1 and anti-PD-L1 antibodies.BOSTON, April 28, 2025  -- Compass Therapeutics, Inc. , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Enhanced Efficacy of CTX-471, A CD137 Agonist Antibody, In Models of Immune Checkpoint Failure Via Simultaneous Blockade of Neo-Angiogenesis” at the Amer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/compass-therapeutics-presents-data-enhanced-120000900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4007","AFG","CMPX","BTC","BK4117","BK4107"],"gpt_icon":0},{"id":"2530000403","title":"Protara Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530000403","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530000403?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2025 08:00 ET (12:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","LENZ"],"gpt_icon":0},{"id":"2530473403","title":"Appili Therapeutics granted new patents for LIKMEZ","url":"https://stock-news.laohu8.com/highlight/detail?id=2530473403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530473403?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:52","pubTimestamp":1745841146,"startTime":"0","endTime":"0","summary":"Appili Therapeutics (APLIF) announced the United States Patent and Trademark Office and the Mexican Patent Office have granted new patent claims pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/appili-therapeutics-granted-new-patents-for-likmez?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/appili-therapeutics-granted-new-patents-for-likmez?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","APLIF"],"gpt_icon":0},{"id":"2530470894","title":"Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2530470894","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530470894?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:35","pubTimestamp":1745840100,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025  -- Alterity Therapeutics  , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Trust of the U.K.“We were honoured to be selected to present the recent data from our double-blind Phase 2 trial,” said, Dr. Stamler. “The Symposium brought together prominent clinicians and researchers from both Europe and the US along with industry scientists, all of whom are focused on increasing their understanding of MSA and advancing new therapies for this aggressive disorder. The strong clinical efficacy data and novel mechanism of ATH434 was well received by this esteemed group of clinicians and academics, as we collectively seek solutions to imp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-presents-ath434-201-113500444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ATH.AU","BK4139","LU1815336091.USD","LU1923622291.USD","LU2211815571.USD","LU2125909759.SGD","BK4007","BK7067","BK4143","LU0728928796.USD","LENZ","LU0757428866.USD","MSA","LU2125909916.SGD","LU0053671581.USD","ATHE"],"gpt_icon":0},{"id":"2530472880","title":"ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472880","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472880?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potentantitumor activity in ovarian and non-small lung cancer. Poster presentations highlightantitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs. ADCT-242 was tolerated in mice or cynomolgus monkeys at doses up to 150 mg/kg or 40 mg/kg, respectively, indicative of a good therapeutic index. Data from the preclinical investigation of ADCT-241, a novel PSMA-targeting ADC, were presented in a poster presentation titled, \"Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer.\" The data demonstrated antitumor activity in both xenograft and patient-derived PSMA-expressing prostate cancer models as well as synergy with enzalutamide. ADCT-241 was well tolerated in both rats and cynomolgus monkeys.Data from the preclinical investigation of HuB14-VA-PL2202, a novel ASCT2-targetingADC, were presented in a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adc-therapeutics-announces-preclinical-data-110000039.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-announces-preclinical-data-110000039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4117","BK4505","ADC","ADCT","BK4007","BK4107","BK4139","BK4080","BK4231","AFG"],"gpt_icon":0},{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4161","BK4117","BK4107","BK4007","RNTX","BK4139","ATS","CSD","AFG"],"gpt_icon":0},{"id":"2530473103","title":"Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2530473103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530473103?lang=en_us&edition=fundamental","pubTime":"2025-04-28 18:16","pubTimestamp":1745835370,"startTime":"0","endTime":"0","summary":"H.C. Wainwright says the HARMONi-2 OS interim data was not powered for statistical significance. It keeps a Buy rating on Summit Therapeutics (SMMT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-selloff-friday-on-data-overdone-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-selloff-friday-on-data-overdone-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","LENZ","BK4007","SMMF"],"gpt_icon":0},{"id":"2530446854","title":"PYC Therapeutics Announces Change in Substantial Shareholder Interests","url":"https://stock-news.laohu8.com/highlight/detail?id=2530446854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530446854?lang=en_us&edition=fundamental","pubTime":"2025-04-28 15:37","pubTimestamp":1745825850,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) has provided an announcement. PYC Therapeutics Limited has announced a change in the interests of a substant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-announces-change-in-substantial-shareholder-interests?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-announces-change-in-substantial-shareholder-interests?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2530441527","title":"Springworks Therapeutics Agrees to $47-Per-Share Takeover Offer From Germany's Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2530441527","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530441527?lang=en_us&edition=fundamental","pubTime":"2025-04-28 15:24","pubTimestamp":1745825054,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics  has agreed to be acquired by German technology firm Merck KGaA for $47 per share in cash, the companies said in a joint statement Monday.The consideration represents about $3.9 billion in equity value, or $3.4 billion in enterprise value, for SprinWorks.The deal is expected to close in H2, subject to regulatory approvals and customary closing conditions.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LU1037948541.HKD","LU1430594728.SGD","LU0320765489.SGD","LU1069347547.HKD","SG9999014567.USD","LU1093756325.SGD","LU0965509010.AUD","LU2089984988.USD","SWTX","IE0009355771.USD","LU1057294990.SGD","SG9999015358.SGD","IE000M9KFDE8.USD","LU0234572021.USD","LU1941712264.USD","LU1929549753.HKD","LU2468319806.SGD","LU0208291251.USD","LU1023059063.AUD","LU0265550359.USD","IE00BJT1NW94.SGD","BK4588","LU0106261372.USD","LU1934455277.USD","LU1934455863.HKD","LU2361044949.HKD","IE00B2B36J28.USD","LU1291159041.SGD","LU1917777945.USD","BK4533","LU0965508806.USD","BK4516","SG9999002224.SGD","LU2361044865.SGD","LU0320765646.SGD","SG9999013999.USD","IE00BJJMRZ35.SGD","MRK","IE0002141913.USD","LU1116320737.USD","SG9999001176.USD","BK4534","LU1066051811.HKD","SGXZ57979304.SGD","LU0965509283.SGD","LU0965509101.SGD","IE00BBT3K403.USD","LU0203345920.USD","LU1116320901.HKD"],"gpt_icon":0},{"id":"2530844822","title":"Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2530844822","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530844822?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:13","pubTimestamp":1745820780,"startTime":"0","endTime":"0","summary":"– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion  –。– Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business –。– SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas –。– Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany’s Healthcare business in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide –。Upon closing, the business combination will immediately contribute to Merck KGaA, Darmstadt, Germany’s reve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-kgaa-darmstadt-germany-acquire-061300678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985320562.USD","LU1037948541.HKD","LU0238689110.USD","LU1929549753.HKD","LU0861579265.USD","MRK","LU1989772840.SGD","BK4137","SG9999001176.USD","SWTX","AAQC","LU2361044865.SGD","SG9999013999.USD","LU2361045086.USD","LU0122379950.USD","LU1162221912.USD","LU2089984988.USD","LU2361044949.HKD","LU0006306889.USD","LU1917777945.USD","BK4007","LU1066053197.SGD","CHMP","PN","LU2023250504.SGD","SG9999015341.SGD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU0234572021.USD","IE00BLSP4239.USD","LU0203347892.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU1069347547.HKD","IE00BFTCPJ56.SGD","LENZ","LU0965509283.SGD","SG9999014575.USD","LU1585245621.USD","SG9999002232.USD","IE0002141913.USD","LU1941712348.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","HCSG","LU1066051498.USD","MAA","LU1989772923.USD","LU0106261372.USD","LU1571399168.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":14,"totalSize":287,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-05-09","current":-15.25222,"percent":0.091255,"low":-16.900596,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"high":-5.069183,"avg":-10.27698,"sd":3.318099,"marketCap":728141003},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003}],"updateTime":1746912718625}}}